Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference

21 Dec 2023
www.globenewswire.com
VaccinemRNA
Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced it has been selected to present in the Private Company Track at the 42nd Annual J.P. Morgan Healthcare Conference.
Curevo’s CEO, George Simeon, will discuss data from Curevo’s 876-patient head to-head trial of CRV-101, a non-mRNA adjuvanted subunit vaccine for shingles, versus Shingrix®.
The presentation will occur on Wednesday, January 10th at 4:00pm Pacific Standard USA Time (PST) in the Golden Gate room (32nd floor).
About Curevo Vaccine
Curevo is a privately held, clinical-stage biotechnology company based in Seattle and dedicated to reducing the burden of infectious disease by developing safe and highly effective vaccines. Its lead product is CRV-101, a non-mRNA sub-unit vaccine to prevent shingles, a serious medical condition involving a blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain. The currently $4 billion shingles vaccine market is characterized by accessibility issues and vaccine hesitancy/dose avoidance related to the burden of vaccine-related side effects. Curevo is also developing a non-live, non-mRNA subunit chickenpox vaccine. For more information visit https://curevovaccine.com/.
Shingrix® is a registered trademark of GlaxoSmithKline, PLC.


For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.